ExonHit Expands Splicearray Line on Affymetrix Microarray Platform
News Apr 18, 2006
ExonHit Therapeutics have announced that a number of its SpliceArray products are now available on the Affymetrix microarray platform.
This announcement follows the supply and provider agreement between ExonHit and Affymetrix signed last October.
ExonHit's SpliceArrays that are now available on the Affymetrix GeneChip® platform include ExonHit's SpliceArrays for GPCR, Ion Channel, nuclear receptors and apoptosis pathways. Custom arrays are also available.
SpliceArrays are a new generation of microarrays that resolve the expression of genes at the level of their alternatively spliced transcripts. Recent publications suggest that over 80% of all human genes undergo alternative splicing, potentially producing many gene products with different functions from a single locus.
With the perceived importance of alternative splicing at an all time high, the need for robust and accurate tools specifically designed to fully interrogate the complete transcriptome is critical for a clearer understanding of the onset of diseases and regulation of biological processes. ExonHit's proprietary SpliceArray content and patented probe configuration achieve this goal.
"This move is a step towards our goal of offering our SpliceArray technology to the marketplace on several platforms, thus providing maximum flexibility to our customers.
Our SpliceArray products are now available on both Agilent and Affymetrix microarray platforms, the two main platforms used routinely in the fields of on-going research, drug discovery and diagnostics," said Bruno Tocque, President of ExonHit's Management Board.
Scientists used a gene editing method called CRISPR/Cas9 to generate mice that faithfully mimic a fatal respiratory disorder in newborn infants that turns their lips and skin blue. The new laboratory model allowed researchers to pinpoint the ailment's cause and develop a potential and desperately needed nanoparticle-based treatment.READ MORE